HIV drug studied in liver transplant patients
NCT ID NCT01022476
First seen Apr 13, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study looked at how the HIV medication raltegravir works in people with HIV who also have end-stage liver disease and need a liver transplant. Researchers wanted to see how the drug interacts with anti-rejection medicines given after transplant. 14 participants were followed before and after their transplant to check drug levels, safety, and whether HIV remained controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Service de Médecine Interne, Hôpital de Bicêtre
Le Kremlin-Bicêtre, 94275, France
Conditions
Explore the condition pages connected to this study.